Login / Signup

Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2.

Anthony P FernandezEsteban DaudénSascha GerdesM G LebwohlM A MenterC L LeonardiMelinda J GooderhamK GebauerYayoi TadaJean-Philippe LacourL BianchiAlexander EgebergI Pau-CharlesA M MendelsohnS J RozzoNehal N Mehta
Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2022)
Tildrakizumab maintains efficacy and a favorable safety profile over 5 years in patients with psoriasis regardless of MetS status.
Keyphrases
  • metabolic syndrome
  • electronic health record
  • atopic dermatitis
  • big data
  • insulin resistance
  • uric acid
  • cardiovascular risk factors
  • cardiovascular disease
  • machine learning
  • data analysis
  • artificial intelligence